Asthma

Nature Reviews Disease Primers

Volumn 1, Issue , 2015, Pages

  Holgate, Stephen T ^a   Wenzel, Sally ^b   Postma, Dirkje S ^c   Weiss, Scott T ^d   Renz, Harald ^e   Sly, Peter D ^f  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY HOSPITAL MARBURG   (Germany)

^f UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN;

ABNORMAL RESPIRATORY SOUND; ASTHMA; COMPLICATION; DISEASE EXACERBATION; GENETIC EPIGENESIS; HUMAN; HYPERSENSITIVITY; PHENOTYPE;

ALLERGENS; ASTHMA; DISEASE PROGRESSION; EPIGENESIS, GENETIC; HUMANS; HYPERSENSITIVITY; PHENOTYPE; RESPIRATORY SOUNDS;

EID: 84995605043     PISSN: None     EISSN: 2056676X     Source Type: Journal    
DOI: 10.1038/nrdp.2015.25     Document Type: Article

References (256)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention GINA [online], http://www.ginasthma.org/local/uploads/files/ GINA-Report-2015-May19.pdf (2015).
2. Lange, P., Parner, J., Vestbo, J., Schnohr, P. & Jensen, G. A 15-year follow-up study of ventilatory function in adults with asthma. N. Engl. J. Med. 339, 1194-1200 (1998).
3. Porsbjerg, C., Lange, P. & Ulrik, C. S. Lung function impairment increases with age of diagnosis in adult onset asthma. Respir. Med. 109, 821-827 (2015).
4. Custovic, A. To what extent is allergen exposure a risk factor for the development of allergic disease? Clin. Exp. Allergy 45, 54-62 (2015).
5. Amelink, M. et al. Severe adult-onset asthma: a distinct phenotype. J. Allergy Clin. Immunol. 132, 336-341 (2013).
6. Ledford, D. K. & Lockey, R. F. Asthma and comorbidities. Curr. Opin. Allergy Clin. Immunol. 13, 78-86 (2013).
7. Custovic, A. et al. EAACI position statement on asthma exacerbations and severe asthma. Allergy 68, 1520-1531 (2013).
8. Fu, L. et al. Natural progression of childhood asthma symptoms and strong influence of sex and puberty. Ann. Am. Thorac. Soc. 11, 939-944 (2014).
9. Soyka, M. B., van de Veen, W., Holzmann, D., Akdis, M. & Akdis, C. A. Scientific foundations of allergen-specific immunotherapy for allergic disease. Chest 146, 1347-1357 (2014).
10. Murray, C. S., Woodcock, A., Langley, S. J., Morris, J. & Custovic, A. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet 368, 754-762 (2006).
11. Murray, C. S. Can inhaled corticosteroids influence the natural history of asthma? Curr. Opin. Allergy Clin. Immunol. 8, 77-81 (2008).
12. Moore, W. C. et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am. J. Respir. Crit. Care Med. 181, 315-323 (2010).
13. World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. WHO [online], http://www. who.int/gard/publications/GARD-Manual/en/ (2007).
14. Wang, D. et al. Cross-sectional epidemiological survey of asthma in Jinan, China. Respirology 18, 313-322 (2013).
15. Jackson, D. J., Hartert, T. V., Martinez, F. D., Weiss, S. T. & Fahy, J. V. Asthma: NHLBI workshop on the primary prevention of chronic lung diseases. Ann. Am. Thorac. Soc. 11, S139-S145 (2014).
16. Yunginger, J. W. et al. A community-based study of the epidemiology of asthma. Incidence rates, 1964-1983. Am. Rev. Respir. Dis. 146, 888-894 (1992).
17. Butland, B. K. & Strachan, D. P. Asthma onset and relapse in adult life: the British 1958 birth cohort study. Ann. Allergy Asthma Immunol. 98, 337-343 (2007).
18. Arshad, S. H. et al. Pathophysiological characterization of asthma transitions across adolescence. Respir. Res. 15, 153 (2014).
19. Szefler, S. J. Advances in pediatric asthma in 2014: moving toward a population health perspective. J. Allergy Clin. Immunol. 135, 644-652 (2015).
20. Dumas, O. et al. Occupational irritants and asthma: an Estonian cross-sectional study of 34,000 adults. Eur. Respir. J. 44, 647-656 (2014).
21. Simpson, A. et al. Beyond atopy: multiple patterns of sensitization in relation to asthma in a birth cohort study. Am. J. Respir. Crit. Care Med. 181, 1200-1206 (2010).
22. Tai, A. et al. Outcomes of childhood asthma to the age of 50 years. J. Allergy Clin. Immunol. 133, 1572-1578.e3 (2014).
23. Wu, W. et al. Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. J. Allergy Clin. Immunol. 133, 1280-1288 (2014).
24. Sporik, R., Holgate, S. T., Platts-Mills, T. A. & Cogswell, J. J. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood - a prospective study. N. Engl. J. Med. 323, 502-507 (1990).
25. Permaul, P. et al. Allergens in urban schools and homes of children with asthma. Pediatr. Allergy Immunol. 23, 543-549 (2012).
26. Olivieri, M. et al. Risk factors for new-onset cat sensitization among adults: a population-based international cohort study. J. Allergy Clin. Immunol. 129, 420-425 (2012).
27. Djukanovic, R. et al. Mucosal inflammation in asthma. Am. Rev. Respir. Dis. 142, 434-457 (1990).
28. Fajt, M. L. & Wenzel, S. E. Mast cells, their subtypes, and relation to asthma phenotypes. Ann. Am. Thorac. Soc. 10, S158-S164 (2013).
29. Brightling, C. E. et al. Mast-cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med. 346, 1699-1705 (2002).
30. Balzar, S. et al. Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program. Am. J. Respir. Crit. Care Med. 183, 299-309 (2011).
31. Holgate, S. T. Innate and adaptive immune responses in asthma. Nat. Med. 18, 673-683 (2012).
32. Fahy, J. V. Type 2 inflammation in asthma - present in most, absent in many. Nat. Rev. Immunol. 15, 57-65 (2015).
33. Truyen, E. et al. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. Thorax 61, 202-208 (2006).
34. Chesné, J. et al. IL-17 in severe asthma. Where do we stand? Am. J. Respir. Crit. Care Med. 190, 1094-1101 (2014).
35. Neill, D. R. et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464, 1367-1370 (2010).
36. Kim, H. Y., DeKruyff, R. H. & Umetsu, D. T. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat. Immunol. 11, 577-584 (2010).
37. Martinez-Gonzalez, I., Steer, C. A. & Takei, F. Lung ILC2s link innate and adaptive responses in allergic inflammation. Trends Immunol. 36, 189-195 (2015).
38. Jain, V. V., Perkins, D. L. & Finn, P. W. Costimulation and allergic responses: immune and bioinformatic analyses. Pharmacol. Ther. 117, 385-392 (2008).
39. Lambrecht, B. N. & Hammad, H. The immunology of asthma. Nat. Immunol. 16, 45-56 (2014).
40. Kay, A. B. The role of T lymphocytes in asthma. Chem. Immunol. Allergy 91, 59-75 (2006).
41. Jacquet, A. Interactions of airway epithelium with protease allergens in the allergic response. Clin. Exp. Allergy 41, 305-311 (2011).
42. Lambrecht, B. N. & Hammad, H. Biology of lung dendritic cells at the origin of asthma. Immunity 31, 412-424 (2009).
43. Kemeny, D. M. The role of the T follicular helper cells in allergic disease. Cell. Mol. Immunol. 9, 386-389 (2012).
44. Perros, F., Hoogsteden, H. C., Coyle, A. J., Lambrecht, B. N. & Hammad, H. Blockade of CCR4 in a humanized model of asthma reveals a critical role for DC-derived CCL17 and CCL22 in attracting Th2 cells and inducing airway inflammation. Allergy 64, 995-1002 (2009).
45. Bradding, P., Walls, A. F. & Holgate, S. T. The role of the mast cell in the pathophysiology of asthma. J. Allergy Clin. Immunol. 117, 1277-1284 (2006).
46. Ma, L. L. & O'Byrne, P. M. The pharmacological modulation of allergen-induced asthma. Inflammopharmacology 21, 113-124 (2013).
47. Hargreave, F. E., Dolovich, J., O'Byrne, P. M., Ramsdale, E. H. & Daniel, E. E. The origin of airway hyperresponsiveness. J. Allergy Clin. Immunol. 78, 825-832 (1986).
48. Diamant, Z. et al. Inhaled allergen bronchoprovocation tests. J. Allergy Clin. Immunol. 132, 1045-1055.e6 (2013).
49. Barnig, C. et al. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci. Transl. Med. 5, 174ra26 (2013).
50. Barbers, R. G. et al. Near fatal asthma: clinical and airway biopsy characteristics. Pulm. Med. 2012, 829608 (2012).
51. Al-Muhsen, S., Johnson, J. R. & Hamid, Q. Remodeling in asthma. J. Allergy Clin. Immunol. 128, 451-462 (2011).
52. Bjermer, L. The role of small airway disease in asthma. Curr. Opin. Pulm. Med. 20, 23-30 (2014).
53. Boucherat, O., Boczkowski, J., Jeannotte, L. & Delacourt, C. Cellular and molecular mechanisms of goblet cell metaplasia in the respiratory airways. Exp. Lung Res. 39, 207-216 (2013).
54. Roche, W. R., Beasley, R., Williams, J. H. & Holgate, S. T. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1, 520-524 (1989).
55. Kanemitsu, Y. et al. Osteopontin and periostin are associated with a 20-year decline of pulmonary function in patients with asthma. Am. J. Respir. Crit. Care Med. 190, 472-474 (2014).
56. Liesker, J. J. W. et al. Reticular basement membrane in asthma and COPD: similar thickness, yet different composition. Int. J. Chron. Obstruct. Pulmon. Dis. 4, 127-135 (2009).
57. Holgate, S. T. et al. Epithelial-mesenchymal communication in the pathogenesis of chronic asthma. Proc. Am. Thorac. Soc. 1, 93-98 (2004).
58. Chanez, P. et al. Platelet-derived growth factor in asthma. Allergy 50, 878-883 (1995).
59. Puddicombe, S. M. et al. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J. 14, 1362-1374 (2000).
60. Olgart Höglund, C. et al. Nerve growth factor levels and localisation in human asthmatic bronchi. Eur. Respir. J. 20, 1110-1116 (2002).
61. Lopez-Guisa, J. M. et al. Airway epithelial cells from asthmatic children differentially express proremodeling factors. J. Allergy Clin. Immunol. 129, 990.e6-997.e6 (2012).
62. Harkness, L. M., Ashton, A. W. & Burgess, J. K. Asthma is not only an airway disease, but also a vascular disease. Pharmacol. Ther. 148, 17-33 (2015).
63. Puddicombe, S. M. et al. Increased expression of p21waf cyclin-dependent kinase inhibitor in asthmatic bronchial epithelium. Am. J. Respir. Cell. Mol. Biol. 28, 61-68 (2003).
64. Alcala, S. E. et al. Mitotic asynchrony induces transforming growth factor-β1 secretion from airway epithelium. Am. J. Respir. Cell. Mol. Biol. 51, 363-369 (2014).
65. Johnson, J. R. et al. Pericytes contribute to airway remodeling in a mouse model of chronic allergic asthma. Am. J. Physiol. Lung Cell. Mol. Physiol. 308, L658-L671 (2015).
66. Descalzi, D. et al. Importance of fibroblasts-myofibroblasts in asthma-induced airway remodeling. Recent Pat. Inflamm. Allergy Drug Discov. 1, 237-241 (2007).
67. Pepe, C. et al. Differences in airway remodeling between subjects with severe and moderate asthma. J. Allergy Clin. Immunol. 116, 544-549 (2005).
68. Glezen, W. P., Taber, L. H., Frank, A. L. & Kasel, J. A. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140, 543-546 (1986).
69. Turner, S. et al. A longitudinal study of lung function from 1 month to 18 years of age. Thorax 69, 1015-1020 (2014).
70. Morgan, W. J. et al. Outcome of asthma and wheezing in the first 6 years of life: follow-up through adolescence. Am. J. Respir. Crit. Care Med. 172, 1253-1258 (2005).
71. Robertson, C. F. Long-term outcome of childhood asthma. Med. J. Aust. 177, S42-S44 (2002).
72. Van Putte-Katier, N. et al. Relationship between parental lung function and their children's lung function early in life. Eur. Respir. J. 38, 664-671 (2011).
73. Soler Artigas, M. et al. Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat. Genet. 43, 1082-1090 (2011).
74. Young, S. et al. The influence of a family history of asthma and parental smoking on airway responsiveness in early infancy. N. Engl. J. Med. 324, 1168-1173 (1991).
75. Latzin, P., Röösli, M., Huss, A., Kuehni, C. E. & Frey, U. Air pollution during pregnancy and lung function in newborns: a birth cohort study. Eur. Respir. J. 33, 594-603 (2009).
76. Stick, S. M., Burton, P. R., Gurrin, L., Sly, P. D. & LeSouëf, P. N. Effects of maternal smoking during pregnancy and a family history of asthma on respiratory function in newborn infants. Lancet 348, 1060-1064 (1996).
77. Sly, P. D., Soto-Quiros, M. E., Landau, L. I., Hudson, I. & Newton-John, H. Factors predisposing to abnormal pulmonary function after adenovirus type 7 pneumonia. Arch. Dis. Child. 59, 935-939 (1984).
78. Sly, P. D. & Hibbert, M. E. Childhood asthma following hospitalization with acute viral bronchiolitis in infancy. Pediatr. Pulmonol. 7, 153-158 (1989).
79. Guilbert, T. W. et al. Decreased lung function after preschool wheezing rhinovirus illnesses in children at risk to develop asthma. J. Allergy Clin. Immunol. 128, 532-538.e10 (2011).
80. Jackson, D. J. et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am. J. Respir. Crit. Care Med. 178, 667-672 (2008).
81. Jackson, D. J. et al. Evidence for a causal relationship between allergic sensitization and rhinovirus wheezing in early life. Am. J. Respir. Crit. Care Med. 185, 281-285 (2012).
82. Wark, P. A. B. et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J. Exp. Med. 201, 937-947 (2005).
83. Edwards, M. R. et al. Impaired innate interferon induction in severe therapy resistant atopic asthmatic children. Mucosal Immunol. 6, 797-806 (2013).
84. Belsky, D. W. & Sears, M. R. The potential to predict the course of childhood asthma. Expert Rev. Respir. Med. 8, 137-141 (2014).
85. Chan, K. N. et al. Airway responsiveness in low birthweight children and their mothers. Arch. Dis. Child. 63, 905-910 (1988).
86. Sonnenschein-van der Voort, A. M. et al. Preterm birth, infant weight gain, and childhood asthma risk: a meta-analysis of 147,000 European children. J. Allergy Clin. Immunol. 133, 1317-1329 (2014).
87. Kennedy, J. D. Lung function outcome in children of premature birth. J. Paediatr. Child Health 35, 516-521 (1999).
88. Strachan, D. P. Hay fever, hygiene, and household size. BMJ 299, 1259-1260 (1989).
89. Renz, H. et al. Gene-environment interactions in chronic inflammatory disease. Nat. Immunol. 12, 273-277 (2011).
90. Litonjua, A. A. & Weiss, S. T. Is vitamin D deficiency to blame for the asthma epidemic? J. Allergy Clin. Immunol. 120, 1031-1035 (2007).
91. Weiss, S. T. Bacterial components plus vitamin D: the ultimate solution to the asthma (autoimmune disease) epidemic? J. Allergy Clin. Immunol. 127, 1128-1130 (2011).
92. Sundar, I. K. & Rahman, I. Vitamin D and susceptibility of chronic lung diseases: role of epigenetics. Front. Pharmacol. 2, 50 (2011).
93. Shaheen, S. O. & Adcock, I. M. The developmental origins of asthma: does epigenetics hold the key? Am. J. Respir. Crit. Care Med. 180, 690-691 (2009).
94. Huang, Y. J. & Boushey, H. A. The microbiome in asthma. J. Allergy Clin. Immunol. 135, 25-30 (2015).
95. Holt, P. G., Strickland, D. H., Hales, B. J. & Sly, P. D. Defective respiratory tract immune surveillance in asthma: a primary causal factor in disease onset and progression. Chest 145, 370-378 (2014).
96. Holt, P. G. Prevention - what is the most promising approach? Pediatr. Allergy Immunol. 25, 12-14 (2014).
97. Hales, B. J. et al. Antibacterial antibody responses associated with the development of asthma in house dust mite-sensitised and non-sensitised children. Thorax 67, 321-327 (2012).
98. Hales, B. J. et al. Differences in the antibody response to a mucosal bacterial antigen between allergic and non-allergic subjects. Thorax 63, 221-227 (2008).
99. Holt, P. G. & Sly, P. D. Viral infections and atopy in asthma pathogenesis: new rationales for asthma prevention and treatment. Nat. Med. 18, 726-735 (2012).
100. Hollams, E. M. et al. Th2-associated immunity to bacteria in teenagers and susceptibility to asthma. Eur. Respir. J. 36, 509-516 (2010).
101. Saglani, S. et al. Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers. Am. J. Respir. Crit. Care Med. 176, 858-864 (2007).
102. Malmström, K. et al. Lung function, airway remodelling and inflammation in symptomatic infants: outcome at 3 years. Thorax 66, 157-162 (2011).
103. Sonnappa, S., Bastardo, C. M., Saglani, S., Bush, A. & Aurora, P. Relationship between past airway pathology and current lung function in preschool wheezers. Eur. Respir. J. 38, 1431-1436 (2011).
104. O'Reilly, R. et al. Increased airway smooth muscle in preschool wheezers who have asthma at school age. J. Allergy Clin. Immunol. 131, 1024-1032.e16 (2013).
105. Regamey, N. et al. Increased airway smooth muscle mass in children with asthma, cystic fibrosis, and non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 177, 837-843 (2008).
106. An, S. S. & Fredberg, J. J. Biophysical basis for airway hyperresponsiveness. Can. J. Physiol. Pharmacol. 85, 700-714 (2007).
107. Grainge, C. L. et al. Effect of bronchoconstriction on airway remodeling in asthma. N. Engl. J. Med. 364, 2006-2015 (2011).
108. Grainge, C. et al. Resistin-like molecule-β is induced following bronchoconstriction of asthmatic airways. Respirology 17, 1094-1100 (2012).
109. Chu, E. K. et al. Induction of the plasminogen activator system by mechanical stimulation of human bronchial epithelial cells. Am. J. Respir. Cell. Mol. Biol. 35, 628-638 (2006).
110. Park, J.-A., Drazen, J. M. & Tschumperlin, D. J. The chitinase-like protein YKL-40 is secreted by airway epithelial cells at base line and in response to compressive mechanical stress. J. Biol. Chem. 285, 29817-29825 (2010).
111. Holgate, S. T. The sentinel role of the airway epithelium in asthma pathogenesis. Immunol. Rev. 242, 205-219 (2011).
112. Bedke, N. et al. Transforming growth factor-beta promotes rhinovirus replication in bronchial epithelial cells by suppressing the innate immune response. PLoS ONE 7, e44580 (2012).
113. Djukanovic, R. et al. The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial. Am. J. Respir. Crit. Care Med. 190, 145-154 (2014).
114. Vink, N. M., Postma, D. S., Schouten, J. P., Rosmalen, J. G. & Boezen, H. M. Gender differences in asthma development and remission during transition through puberty: the TRacking Adolescents' Individual Lives Survey (TRAILS) study. J. Allergy Clin. Immunol. 126, 498-504.e6 (2010).
115. Van den Toorn, L. M. et al. Airway inflammation is present during clinical remission of atopic asthma. Am. J. Respir. Crit. Care Med. 164, 2107-2113 (2001).
116. Wood, R. A., Laheri, A. N. & Eggleston, P. A. The aerodynamic characteristics of cat allergen. Clin. Exp. Allergy 23, 733-739 (1993).
117. Vonk, J. M. et al. Childhood factors associated with asthma remission after 30 year follow up. Thorax 59, 925-929 (2004).
118. Broekema, M. et al. Airway eosinophilia in remission and progression of asthma: accumulation with a fast decline of FEV1. Respir. Med. 104, 1254-1262 (2010).
119. Broekema, M. et al. Persisting remodeling and less airway wall eosinophil activation in complete remission of asthma. Am. J. Respir. Crit. Care Med. 183, 310-316 (2011).
120. Volbeda, F. et al. Can AMP induce sputum eosinophils, even in subjects with complete asthma remission? Respir. Res. 11, 106 (2010).
121. Shaaban, R. et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 372, 1049-1057 (2008).
122. Platts-Mills, T., Vaughan, J., Squillace, S., Woodfolk, J. & Sporik, R. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet 357, 752-756 (2001).
123. Torrent, M. et al. Early-life allergen exposure and atopy, asthma, and wheeze up to 6 years of age. Am. J. Respir. Crit. Care Med. 176, 446-453 (2007).
124. Scott, M. et al. Multifaceted allergen avoidance during infancy reduces asthma during childhood with the effect persisting until age 18 years. Thorax 67, 1046-1051 (2012).
125. Kovac, K., Dodig, S., Tjesic-Drinkovic, D. & Raos, M. Correlation between asthma severity and serum IgE in asthmatic children sensitized to Dermatophagoides pteronyssinus. Arch. Med. Res. 38, 99-105 (2007).
126. Adgate, J. L., Ramachandran, G., Cho, S. J., Ryan, A. D. & Grengs, J. Allergen levels in inner city homes: baseline concentrations and evaluation of intervention effectiveness. J. Expo. Sci. Environ. Epidemiol. 18, 430-440 (2008).
127. MacDonald, C., Sternberg, A. & Hunter, P. R. A systematic review and meta-analysis of interventions used to reduce exposure to house dust and their effect on the development and severity of asthma. Environ. Health Perspect. 115, 1691-1695 (2007).
128. Van Schayck, O. C., Maas, T., Kaper, J., Knottnerus, A. J. & Sheikh, A. Is there any role for allergen avoidance in the primary prevention of childhood asthma? J. Allergy Clin. Immunol. 119, 1323-1328 (2007).
129. Braun-Fahrländer, C. et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N. Engl. J. Med. 347, 869-877 (2002).
130. Ege, M. J. et al. Exposure to environmental microorganisms and childhood asthma. N. Engl. J. Med. 364, 701-709 (2011).
131. Heederik, D. & von Mutius, E. Does diversity of environmental microbial exposure matter for the occurrence of allergy and asthma? J. Allergy Clin. Immunol. 130, 44-50 (2012).
132. Renz, H., Brandtzaeg, P. & Hornef, M. The impact of perinatal immune development on mucosal homeostasis and chronic inflammation. Nat. Rev. Immunol. 12, 9-23 (2011).
133. Carroll, K. N. et al. Season of infant bronchiolitis and estimates of subsequent risk and burden of early childhood asthma. J. Allergy Clin. Immunol. 123, 964-966 (2009).
134. Jackson, D. J. & Lemanske, R. F. The role of respiratory virus infections in childhood asthma inception. Immunol. Allergy Clin. North Am. 30, 513-522 (2010).
135. Durrani, S. R. et al. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J. Allergy Clin. Immunol. 130, 489-495 (2012).
136. Mortensen, L. J., Kreiner-Møller, E., Hakonarson, H., Bønnelykke, K. & Bisgaard, H. The PCDH1 gene and asthma in early childhood. Eur. Respir. J. 43, 792-800 (2014).
137. Bønnelykke, K. et al. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. Nat. Genet. 46, 51-55 (2014).
138. Klaassen, E. M. et al. An ADAM33 polymorphism associates with progression of preschool wheeze into childhood asthma: a prospective case-control study with replication in a birth cohort study. PLoS ONE 10, e0119349 (2015).
139. Huang, S.-K., Zhang, Q., Qiu, Z. & Chung, K. F. Mechanistic impact of outdoor air pollution on asthma and allergic diseases. J. Thorac. Dis. 7, 23-33 (2015).
140. Guarnieri, M. & Balmes, J. R. Outdoor air pollution and asthma. Lancet 383, 1581-1592 (2014).
141. Chan, J. K. et al. Combustion-derived flame generated ultrafine soot generates reactive oxygen species and activates Nrf2 antioxidants differently in neonatal and adult rat lungs. Part. Fibre Toxicol. 10, 34 (2013).
142. Wang, P., Thevenot, P., Saravia, J., Ahlert, T. & Cormier, S. A. Radical-containing particles activate dendritic cells and enhance Th17 inflammation in a mouse model of asthma. Am. J. Respir. Cell. Mol. Biol. 45, 977-983 (2011).
143. Nadeau, K. et al. Ambient air pollution impairs regulatory T-cell function in asthma. J. Allergy Clin. Immunol. 126, 845-852.e10 (2010).
144. Gowers, A. M. et al. Does outdoor air pollution induce new cases of asthma? Biological plausibility and evidence; a review. Respirology 17, 887-898 (2012).
145. Goodman, J. E., Chandalia, J. K., Thakali, S. & Seeley, M. Meta-analysis of nitrogen dioxide exposure and airway hyper-responsiveness in asthmatics. Crit. Rev. Toxicol. 39, 719-742 (2009).
146. Gauderman, W. J. et al. Association of improved air quality with lung development in children. N. Engl. J. Med. 372, 905-913 (2015).
147. Yang, I. A., Fong, K. M., Zimmerman, P. V., Holgate, S. T. & Holloway, J. W. Genetic susceptibility to the respiratory effects of air pollution. Postgrad. Med. J. 85, 428-436 (2009).
148. Esposito, S. et al. Possible molecular mechanisms linking air pollution and asthma in children. BMC Pulm. Med. 14, 31 (2014).
149. Vork, K. L., Broadwin, R. L. & Blaisdell, R. J. Developing asthma in childhood from exposure to secondhand tobacco smoke: insights from a meta-regression. Environ. Health Perspect. 115, 1394-1400 (2007).
150. Burke, H. et al. Prenatal and passive smoke exposure and incidence of asthma and wheeze: systematic review and meta-analysis. Pediatrics 129, 735-744 (2012).
151. Feleszko, W. et al. Parental tobacco smoking is associated with augmented IL-13 secretion in children with allergic asthma. J. Allergy Clin. Immunol. 117, 97-102 (2006).
152. Li, Y.-F., Langholz, B., Salam, M. T. & Gilliland, F. D. Maternal and grandmaternal smoking patterns are associated with early childhood asthma. Chest 127, 1232-1241 (2005).
153. Mebrahtu, T. F., Feltbower, R. G., Greenwood, D. C. & Parslow, R. C. Childhood body mass index and wheezing disorders: a systematic review and meta-analysis. Pediatr. Allergy Immunol. 26, 62-72 (2015).
154. Forno, E., Young, O. M., Kumar, R., Simhan, H. & Celedon, J. C. Maternal obesity in pregnancy, gestational weight gain, and risk of childhood asthma. Pediatrics 134, e535-e546 (2014).
155. Torday, J. S. et al. Leptin mediates the parathyroid hormone-related protein paracrine stimulation of fetal lung maturation. Am. J. Physiol. Lung Cell. Mol. Physiol. 282, L405-L410 (2002).
156. Shore, S. A. et al. Effect of leptin on allergic airway responses in mice. J. Allergy Clin. Immunol. 115, 103-109 (2005).
157. McLachlan, C. R. et al. Adiposity, asthma, and airway inflammation. J. Allergy Clin. Immunol. 119, 634-639 (2007).
158. Kattan, M. et al. Asthma control, adiposity, and adipokines among inner-city adolescents. J. Allergy Clin. Immunol. 125, 584-592 (2010).
159. Aaron, S. D. et al. Overdiagnosis of asthma in obese and nonobese adults. CMAJ 179, 1121-1131 (2008).
160. [No authors listed.] Statement on standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am. Rev. Respir. Dis. 136, 225-244 (1987).
161. National Institute for Health and Care Excellence. Asthma: diagnosis and monitoring of asthma in adults, children and young people. NICE [online], http:// www.nice.org.uk/guidance/gid-cgwave0640/resources/ asthma-diagnosis-and-monitoring-draft-guideline2 (2015).
162. Pavord, I. D., Bush, A. & Holgate, S. Asthma diagnosis: addressing the challenges. Lancet Respir. Med. 3, 339-341 (2015).
163. Wenzel, S. E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 18, 716-725 (2012).
164. Corren, J. et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365, 1088-1098 (2011).
165. Woodruff, P. G. et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am. J. Respir. Crit. Care Med. 180, 388-395 (2009).
166. Green, R. H. et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360, 1715-1721 (2002).
167. Jayaram, L. et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur. Respir. J. 27, 483-494 (2006).
168. Bel, E. H. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 371, 1189-1197 (2014).
169. Pavord, I. D. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380, 651-659 (2012).
170. Guo, F. H. et al. Interferon γ and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. J. Clin. Invest. 100, 829-838 (1997).
171. Modena, B. D. et al. Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways. Am. J. Respir. Crit. Care Med. 190, 1363-1372 (2014).
172. Smith, A. D. et al. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am. J. Respir. Crit. Care Med. 169, 473-478 (2004).
173. Wenzel, S. et al. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 368, 2455-2466 (2013).
174. Hanania, N. A. et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am. J. Respir. Crit. Care Med. 187, 804-811 (2013).
175. Takayama, G. et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J. Allergy Clin. Immunol. 118, 98-104 (2006).
176. Sidhu, S. S. et al. Roles of epithelial cell-derived periostin in TGF-β activation, collagen production, and collagen gel elasticity in asthma. Proc. Natl Acad. Sci. USA 107, 14170-14175 (2010).
177. Conway, S. J. et al. The role of periostin in tissue remodeling across health and disease. Cell. Mol. Life Sci. 71, 1279-1288 (2014).
178. Jia, G. et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J. Allergy Clin. Immunol. 130, 647-654.e10 (2012).
179. Izuhara, K. et al. Periostin in allergic inflammation. Allergol. Int. 63, 143-151 (2014).
180. Schulman, E. S. & Pohlig, C. Rationale for specific allergen testing of patients with asthma in the clinical pulmonary office setting. Chest 147, 251-258 (2015).
181. Ortega, H. G. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198-1207 (2014).
182. Choy, D. F. et al. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci. Transl. Med. 7, 301ra129 (2015).
183. Mauri, P. et al. Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunol. Lett. 162, 2-10 (2014).
184. Duncan, J. M. & Sears, M. R. Breastfeeding and allergies: time for a change in paradigm? Curr. Opin. Allergy Clin. Immunol. 8, 398-405 (2008).
185. Kramer, M. S. Breastfeeding and allergy: the evidence. Ann. Nutr. Metab. 59, S20-S26 (2011).
186. Oddy, W. H., Peat, J. K. & de Klerk, N. H. Maternal asthma, infant feeding, and the risk of asthma in childhood. J. Allergy Clin. Immunol. 110, 65-67 (2002).
187. Sears, M. R. et al. Long-term relation between breastfeeding and development of atopy and asthma in children and young adults: a longitudinal study. Lancet 360, 901-907 (2002).
188. Dogaru, C. M., Nyffenegger, D., Pescatore, A. M., Spycher, B. D. & Kuehni, C. E. Breastfeeding and childhood asthma: systematic review and meta-analysis. Am. J. Epidemiol. 179, 1153-1167 (2014).
189. Ramos, G. F. et al. Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model. Eur. J. Health Econ. 15, 869-883 (2014).
190. Litonjua, A. A. et al. The Vitamin D Antenatal Asthma Reduction Trial (VDAART): rationale, design, and methods of a randomized, controlled trial of vitamin D supplementation in pregnancy for the primary prevention of asthma and allergies in children. Contemp. Clin. Trials 38, 37-50 (2014).
191. Yang, H., Xun, P. & He, K. Fish and fish oil intake in relation to risk of asthma: a systematic review and meta-analysis. PLoS ONE 8, e80048 (2013).
192. Anandan, C., Nurmatov, U. & Sheikh, A. Omega 3 and 6 oils for primary prevention of allergic disease: systematic review and meta-analysis. Allergy 64, 840-848 (2009).
193. Von Mutius, E. & Vercelli, D. Farm living: effects on childhood asthma and allergy. Nat. Rev. Immunol. 10, 861-868 (2010).
194. Elazab, N. et al. Probiotic administration in early life, atopy, and asthma: a meta-analysis of clinical trials. Pediatrics 132, e666-e676 (2013).
195. West, C. E., Hammarstr-m, M.-L. & Hernell, O. Probiotics in primary prevention of allergic disease - follow-up at 8-9 years of age. Allergy 68, 1015-1020 (2013).
196. Bengmark, S. Gut microbiota, immune development and function. Pharmacol. Res. 69, 87-113 (2013).
197. Nieto, A. et al. Allergy and asthma prevention 2014. Pediatr. Allergy Immunol. 25, 516-533 (2014).
198. Heine, R. G. Preventing atopy and allergic disease. Nestle Nutr. Inst. Workshop Ser. 78, 141-153 (2014).
199. Tamblyn, R. et al. Evaluating the impact of an integrated computer-based decision support with person-centered analytics for the management of asthma in primary care: a randomized controlled trial. J. Am. Med. Inform. Assoc. 22, 773-783 (2015).
200. Griffiths, C. & Levy, M. L. Preventing avoidable asthma deaths. Practitioner 258, 27-31 (2014).
201. Toelle, B. G. & Ram, F. S. Written individualised management plans for asthma in children and adults. Cochrane Database Syst. Rev. 2, CD002171 (2004).
202. Depner, M. et al. Clinical and epidemiologic phenotypes of childhood asthma. Am. J. Respir. Crit. Care Med. 189, 129-138 (2014).
203. Pedersen, S. E. et al. Global strategy for the diagnosis and management of asthma in children 5 years and younger. Pediatr. Pulmonol. 46, 1-17 (2011).
204. Roberts, N. J. et al. The development and comprehensibility of a pictorial asthma action plan. Patient Educ. Couns. 74, 12-18 (2009).
205. National Heart Lung and Blood Advisory Council Asthma Expert Working Group. Draft needs assessment report for potential update of the expert panel report-3 (2007): guidelines for the diagnosis and management of asthma January 2015. NIH [online], http://www.nhlbi.nih.gov/sites/ www.nhlbi.nih.gov/files/NHLBAC-Asthma-WG-Report-2015%5B1%5D.pdf (2015).
206. British Thoracic Society & Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 69, S1-S192 (2014).
207. Papi, A. et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir. Med. 1, 23-31 (2013).
208. Lipworth, B. J. Emerging role of long acting muscarinic antagonists for asthma. Br. J. Clin. Pharmacol. 77, 55-62 (2014).
209. Matera, M. G. & Cazzola, M. Ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? Drugs 67, 503-515 (2007).
210. Loymans, R. J. B. et al. Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis. BMJ 348, g3009 (2014).
211. Abramson, M. J., Puy, R. M. & Weiner, J. M. Injection allergen immunotherapy for asthma. Cochrane Database Syst. Rev. 8, CD001186 (2010).
212. Mosbech, H. et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 134, 568-575.e7 (2014).
213. Kelly, W., Massoumi, A. & Lazarus, A. Asthma in pregnancy: physiology, diagnosis, and management. Postgrad. Med. 127, 349-358 (2015).
214. Price, D. et al. Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness. Curr. Allergy Asthma Rep. 11, 526-538 (2011).
215. Qamar, N., Pappalardo, A. A., Arora, V. M. & Press, V. G. Patient-centered care and its effect on outcomes in the treatment of asthma. Patient Relat. Outcome Meas. 2, 81-109 (2011).
216. Hinks, T. S. C. et al. Innate and adaptive T cells in asthmatic patients: relationship to severity and disease mechanisms. J. Allergy Clin. Immunol. 136, 323-333 (2015).
217. Holgate, S. T. Stratified approaches to the treatment of asthma. Br. J. Clin. Pharmacol. 76, 277-291 (2013).
218. Campo, P. et al. Phenotypes and endotypes of uncontrolled severe asthma: new treatments. J. Investig. Allergol. Clin. Immunol. 23, 76-88 (2013).
219. Krug, N. et al. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N. Engl. J. Med. 372, 1987-1995 (2015).
220. Hambly, N. & Nair, P. Monoclonal antibodies for the treatment of refractory asthma. Curr. Opin. Pulm. Med. 20, 87-94 (2014).
221. Lima, J. J. Do genetic polymorphisms alter patient response to inhaled bronchodilators? Expert Opin. Drug Metab. Toxicol. 10, 1231-1240 (2014).
222. Zuurhout, M. J. L. et al. Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting β2-agonists: results of the PACMAN cohort. Pharmacogenomics 14, 1965-1971 (2013).
223. Manoharan, A. et al. β2-adrenergic receptor Gly16Arg polymorphism and impaired asthma control in corticosteroid-treated asthmatic adults. Ann. Allergy. Asthma Immunol. 114, 421-423 (2015).
224. Ortega, V. E. et al. Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic study. Lancet Respir. Med. 2, 204-213 (2014).
225. Meyers, D. A., Bleecker, E. R., Holloway, J. W. & Holgate, S. T. Asthma genetics and personalised medicine. Lancet Respir. Med. 2, 405-415 (2014).
226. Miller, R. J. & Murgu, S. D. Interventional pulmonology for asthma and emphysema: bronchial thermoplasty and bronchoscopic lung volume reduction. Semin. Respir. Crit. Care Med. 35, 655-670 (2014).
227. Castro, M., Cox, G., Wechsler, M. E. & Niven, R. M. Bronchial thermoplasty: ready for prime time - the evidence is there! Chest 147, e73-e74 (2015).
228. Pretolani, M. et al. Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma. Am. J. Respir. Crit. Care Med. 190, 1452-1454 (2014).
229. Sheshadri, A., McKenzie, M. & Castro, M. Critical review of bronchial thermoplasty: where should it fit into asthma therapy? Curr. Allergy Asthma Rep. 14, 470 (2014).
230. Iyer, V. N. & Lim, K. G. Bronchial thermoplasty: reappraising the evidence (or lack thereof). Chest 146, 17-21 (2014).
231. Ducharme, F. M., Tse, S. M. & Chauhan, B. Diagnosis, management, and prognosis of preschool wheeze. Lancet 383, 1593-1604 (2014).
232. Guilbert, T. W. et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N. Engl. J. Med. 354, 1985-1997 (2006).
233. Busse, W. W. et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N. Engl. J. Med. 364, 1005-1015 (2011).
234. Wasfi, Y. S. et al. Onset and duration of attenuation of exercise-induced bronchoconstriction in children by single-dose of montelukast. Allergy Asthma Proc. 32, 453-459 (2011).
235. Schultz, A. & Brand, P. L. Phenotype-directed treatment of pre-school-aged children with recurrent wheeze. J. Paediatr. Child Health 48, E73-E78 (2012).
236. Lemanske, R. F. et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N. Engl. J. Med. 362, 975-985 (2010).
237. Martinez, F. D. The connection between early life wheezing and subsequent asthma: the viral march. Allergol. Immunopathol. (Madr.) 37, 249-251 (2009).
238. Martinez, F. D. & Vercelli, D. Asthma. Lancet 382, 1360-1372 (2013).
239. Van Asperen, P. P., Mellis, C. M., Sly, P. D. & Robertson, C. F. Evidence-based asthma management in children - what's new? Med. J. Aust. 194, 383-384 (2011).
240. Zeiger, R. S. et al. Daily or intermittent budesonide in preschool children with recurrent wheezing. N. Engl. J. Med. 365, 1990-2001 (2011).
241. Beigelman, A. et al. Do oral corticosteroids reduce the severity of acute lower respiratory tract illnesses in preschool children with recurrent wheezing? J. Allergy Clin. Immunol. 131, 1518-1525 (2013).
242. Pelkonen, A. S. et al. The effect of montelukast on respiratory symptoms and lung function in wheezy infants. Eur. Respir. J. 41, 664-670 (2013).
243. Wechsler, M. E. Getting control of uncontrolled asthma. Am. J. Med. 127, 1049-1059 (2014).
244. Worth, A. et al. Patient-reported outcome measures for asthma: a systematic review. NPJ Prim. Care Respir. Med. 24, 14020 (2014).
245. Juniper, E. Measurement of health-related quality of life and asthma control. Quoltech [online], http:// www.qoltech.co.uk/questionnaires.htm
246. Chen, H. et al. Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease. J. Allergy Clin. Immunol. 120, 396-402 (2007).
247. Lurie, A., Marsala, C., Hartley, S., Bouchon-Meunier, B. & Dusser, D. Patients' perception of asthma severity. Respir. Med. 101, 2145-2152 (2007).
248. Haselkorn, T. et al. Effect of weight change on asthma-related health outcomes in patients with severe or difficult-to-treat asthma. Respir. Med. 103, 274-283 (2009).
249. Hanania, N. A. et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann. Intern. Med. 154, 573-582 (2011).
250. Castro, M. et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am. J. Respir. Crit. Care Med. 181, 116-124 (2010).
251. Earnshaw, V. A. & Quinn, D. M. The impact of stigma in healthcare on people living with chronic illnesses. J. Health Psychol. 17, 157-168 (2012).
252. Comer, B. S., Ba, M., Singer, C. A. & Gerthoffer, W. T. Epigenetic targets for novel therapies of lung diseases. Pharmacol. Ther. 147, 91-110 (2015).
253. Boutin, H. & Boulet, L.-P. L'asthme au Quotidien (Press Universite Laval, 2005).
254. Bousquet, J., Bousquet, P. J., Godard, P. & Dyres, J.-P. The public health implications of asthma. Bull. World Health Organ. 93, 548-554 (2005).
255. Holgate, S. T. et al. A new look at the pathogenesis of asthma. Clin. Sci. 118, 439-450 (2009).
256. Bateman, E. D. et al. Overall asthma control: the relationship between current control and future risk. J. Allergy Clin. Immunol. 125, 600-608.e6 (2010).